Examples of 'anti-vegf' in a sentence
Meaning of "anti-vegf"
Anti-VEGF refers to a type of medication or treatment that inhibits vascular endothelial growth factor, used in the treatment of various eye conditions
How to use "anti-vegf" in a sentence
Basic
Advanced
anti-vegf
A specific example of an anti-VEGF antibody is bevacizumab.
The anti-VEGF antibodies of the disclosure can be humanized.
These drugs are known as anti-VEGF agents.
Prepare to discuss anti-VEGF therapy at your diagnosis consultation.
These drugs are considered to be anti-VEGF agents.
Use of anti-VEGF antibodies for the treatment of cancer.
Further example antibodies include anti-VEGF antibodies.
More preferably the anti-VEGF antibody is bevacizumab or ranibizumab.
The present disclosure provides anti-VEGF antibodies.
The stability of anti-VEGF was evaluated in various buffer conditions.
The example herein concerns an anti-VEGF antibody.
The anti-VEGF antibody may be administered by intravenous administration.
In some embodiments the anti-VEGF antibody is bevacizumab.
The anti-VEGF antibodies of the disclosure can be primatized.
A method of making an anti-VEGF antibody is also provided.
See also
It is often more prudent to inject triamcinolone or anti-VEGF drugs.
Can be treated with laser or anti-VEGF intravitreal injections.
In various embodiments an agent of the invention is an anti-VEGF agent.
Examples of the anti-VEGF antibody may include bevacizumab.
In one embodiment the antibody is an anti-VEGF antibody.
Concomitant use of other anti-VEGF vascular endothelial growth factor.
The anti-VEGF antibodies of the disclosure can be bispecific antibodies.
Further exemplary embodiments of anti-VEGF antibodies are provided below.
The anti-VEGF antibody is bevacizumab and the chemotherapeutic is paclitaxel.
One example of a method of producing anti-VEGF is described herein.
In some examples, the anti-VEGF antibody is administered by intravenous administration.
The presence of a microhole was discarded, therefore anti-VEGF therapy was resumed.
In some embodiments, the anti-VEGF antibody is administered by intravenous administration.
The active agent in the composition is the anti-VEGF antibody.
Figure 2 depicts analysis of an anti-VEGF monoclonal antibody by capillary electrophoresis.
The anti-VEGF antibodies of the disclosure include derivatized antibodies.
Plates were then incubated with biotinylated polyclonal anti-VEGF antibody.
A tumor resistant to anti-VEGF treatment is an example of a relapse tumor growth.
An increased stromal cell recruitment was observed after anti-VEGF treatment.
The anti-VEGF antibodies of the disclosure can be human antibodies.
Early marker of proteinuria in patients treated with an anti-VEGF treatment.
In some variations, the anti-VEGF antibody is administered by intravenous administration.
At least one active agent in the composition is an anti-VEGF antibody.
The anti-VEGF antibodies of the disclosure can be chimeric antibodies.
Various methods for preparing human anti-VEGF antibodies are provided herein.
Construction of the phagemid vector and the initial humanized anti-VEGF.
The mechanisms underlying anti-VEGF associated hypertension are not understood.
The human can be a human who received the anti-VEGF therapy.
In certain aspects, an anti-VEGF antibody is conjugated to a small molecule toxin.
Assessment of anti-angiogenic in vivo biologic effects of anti-VEGF peptide vaccines.
In certain aspects, the anti-VEGF antibody is conjugated to a small molecule toxin.
A variety of radionuclides are available for the production of radioconjugated anti-VEGF antibodies.
Methods of producing anti-VEGF antibodies by culturing host cells are also provided.
In some embodiments, the additional therapeutic agent is an anti-VEGF therapeutic agent.
In certain embodiments, the anti-VEGF antibody is bevacizumab or a fragment or variant thereof.
